Successive oncogenic steps are necessary t o generate cancer. In many B-cell lymphomas, chromosomal translocations are considered t o be an early oncogenic hit. We investigated whether the lymphoma-associated t(14; 18) involving the BCLZoncogene can occur outside the context of malignancy. To this end, we extensively screened blood cells from healthy blood donors by a very sensitive seminested polymerase chain reaction (PCR) for breakpoint junctions at JH1-5 on 14q32 and the major breakpoint region of BCL2 on 18q21. In each individual, mononuclear cells, granulocytes, flow-sorted B cells, and T cells were separately tested in five t o seven independently performed PCRs (in total, 0.5 x IO6 t o 1.0 x 10' cells per fraction per individual). Amplification products that hybridized with an internal BCLZ probe and a JH probe were sequenced. Six of nine individuals harbored t(14;18) breakpoints. Translocations were restricted t o B INCE THE DESCRIPTION of the translocation t(8; 14)
Successive oncogenic steps are necessary t o generate cancer. In many B-cell lymphomas, chromosomal translocations are considered t o be an early oncogenic hit. We investigated whether the lymphoma-associated t(14; 18) involving the BCLZoncogene can occur outside the context of malignancy. To this end, we extensively screened blood cells from healthy blood donors by a very sensitive seminested polymerase chain reaction (PCR) for breakpoint junctions at JH1-5 on 14q32 and the major breakpoint region of BCL2 on 18q21. In each individual, mononuclear cells, granulocytes, flow-sorted B cells, and T cells were separately tested in five t o seven independently performed PCRs (in total, 0.5 x IO6 t o 1.0 x 10' cells per fraction per individual). Amplification products that hybridized with an internal BCLZ probe and a JH probe were sequenced. Six of nine individuals harbored t(14;18) breakpoints. Translocations were restricted t o B INCE THE DESCRIPTION of the translocation t (8; 14) in Burkitt's lymphoma in 1972,' evidence has accumulated that chromosomal translocations are of prime importance in the genesis of B-cell lymphomas. The most frequently described translocations are t(8;14) in Burkitt's lymphoma, t( 14; 18) in follicular lymphoma, and t( I 1; 14) in mantle cell lymphoma. These translocations involve Ig gene loci and the oncogenes MYC, BCL2, and CCNDI, respectively. Molecular analysis of t(14; 18), t(l1; 14) , and a part of the breakpoints t (8; 14) suggests that they are generated as an illegitimate recombinase-mediated Ig heavy chain (IgH) VDJ rearrangement in bone marrow (BM) precursor B cells or during Ig class switching within the follicle center cell
The early origin of t(14; 18) breakpoints is supported by the sporadic occurrence of precursor B-cell leukemia in follicular lymphoma patients.' In addition, 3q27 breakpoints involving the BCM oncogene are detected in large B-cell lymphoma.' The origin of these breakpoints is largely unknown.
In follicular lymphoma, t(14; 1 S) results in deregulation of the BCL2 proto-oncogene. The translocation confers a survival advantage to the affected cells by prevention of apoptotic death, especially during the follicle center react i~n .~. "
However, deregulation of BCL2 alone seems to be insufficient to establish a fully malignant phenotype. This is Sequence analysis showed that four of six individuals harbored t w o t o five unrelated t(l4;18)-carrying B-cell clones. All breakpoints had a structure similar to that in follicular lymphoma. We propose that B cells with the t(14; 18) translocation are regularly generated in normal individuals, but that only very few cells with the translocation will acquire the additional oncogenic hits necessary t o establish the malignant phenotype. supported by experiments with transfected cell lines and data obtained from transgenic mice.'"14 BCL2IIgH transgenic mice show accumulation of resting B cells but develop malignant lymphoma only after a long latency period and acquisition of secondary oncogenic hits. Therefore, we speculated that t(14; 18) might be present in blood B cells of healthy individuals. Previously, we reported on the detection of rare t( 14; 18) translocations in lymphoid tissues with overt follicular hyperp1a~ia.l~ However, experiments by others on normal blood and BM samples, performed as negative controls for the detection of minimal residual disease in t( 14; 18)-positive lymphoma, did not detect such circulating t( 14; 18)-positive cells in normal individuals.16"'
We report that using a very sensitive, seminested polymerase chain reaction (PCR), one or more circulating B-cell clones with t(14; 18) can be identified in many healthy individuals. These translocations can be detected when purified blood B cells are subjected to multiple PCRs and DNA sequencing. Apparently, these translocations in B cells must be followed by additional oncogenic events to generate a follicular lymphoma. The third bar (BCUIlgH) shows the configuration of a BCLZIJH3 breakpoint with the downstream J H gene segments and the annealing sites of the primer BCU-MBR2 and the JH5-specific primer used during stage 1 PCR. Note that this pair of primers will generate smaller products if a breakpoint had occurred at JH4 or JH5. N. the position of the N-region (in this particular breakpoint, l0 nucleotides). The fourth bar shows the PCR product generated during stage 1 and the localization and size of the regions hybridizing with the J H and BCUprobes. The fifth bar shows the annealing sites of the consensus J H primer and BCU-MBR2 primer used during stage 2 of the seminested PCR. The consensus primer will anneal at all available downstream JH segments and, together with t h e BCU-MBR2 primer, will generate three different products with a predicted difference in size of 373 and 445 bp. These are shown in the lower three bars. Note that only the intensity of the signal obtained with the internal BCU-MB3.5 probe reflects the true copy numbers of PCR products. In contrast, the differences in length of the template for the 2.5-kb J H probe will result in different intensities of stage 2 PCR products when hybridized with the genomic J H probe. Similarly, the intensity of the products visualized in ethidium bromide-stained gels (Fig 2A) will depend on both the copy numbers and length of the amplicons.
The PCR strategy for detection of BCL2IJH breakpoints was as follows. In the first stage of seminested PCR (stage I PCR; Fig I) , 36 cycles of amplification were applied on 1 pg of genomic DNA (containing approximately 1.0 X 10' to 1.5 X IO5 cells) in 50 pL PCR buffer with 30 pmol of the primer BCL2-MBR2 and a JH5 primer (5'-TGCAAGCTGAGTCTCCCTAA-3'). For seminested reamplification (stage 2 PCR ; Fig l) , a 7-pL aliquot of stage 1 product was diluted in distilled water up to a volume of 50 pL, and from this dilution, a 7-pL aliquot was used. The same BCL2-MBR2 primer and a JH consensus primer (5'-ACCTGAGGAGACGGTGAC-3')'9 were used. In both stages, a touchdown PCR was applied with an initial denaturation at 95°C for 5 minutes, followed by 36 cycles of denaturation for I minute at 95°C; annealing temperature starting at 65°C (ie, 2.5"C to 5 Gel analysis and hybridization. Stage 2 products (1 2 pL) were size-fractionated on 1.5% agarose gel (GIBCO BRL. Gaithersburg, MD) and visualized under ultraviolet (UV) light (eg, Fig 2A) . DNA was transferred to Hybond-N' (Amersham, UK) and hybridized with a "P-deoxyadenosine triphosphate (dATP Amersham) end-labeled internal BCL2-MBR3.5 oligonucleotide probe (5'-GCCTGTITC-AACACAGACCC-3'; Fig 2C) and with a 2.5-kb EcoRIIBgl 11 probe for JH (provided by Dr Ph. Leder, Howard Hughes Medical Institute and Harvard Medical School, Boston, MA) labeled with "P-deoxycytidine triphosphate (dCTP) using a random-primed labeling kit according to the manufacturer's instructions (Pharmacia, Uppsala, Sweden; Fig 2B) . Autoradiographs were exposed both for 3 hours and overnight (ON). PCR products that hybridized with both probes were considered as positive (see Control for Contamination for criteria used to exclude contamination artifacts). Positive products that were visible on gel were purified for nucleotide sequence analysis.
DNA sequencing. DNA sequencing of positive PCR products was performed either on PCR products cloned in M13 or by direct sequencing. Single strand sequencing by M13 cloning was performed as described.'" Briefly, the reamplification (stage 2 PCR) was repeated with the same primers as mentioned above and extended with nucleotides for the restriction sites Xba I or Sal I, enabling cloning in M 13tgl3 I RF DNA. Individual PCR products were purified from agarose gel by cutting out (NA agarose, Pharmacia), digested with Sal I and Xbn I, ligated into M13tg131RF digested (Xha I/Sa/ I) vector, and transformed into Escherichia coli JMlOl (enabling lac-recombinant phage selection).
To select for recombinants with BCU sequences, plaque lifting was performed, followed by hybridization of the filters with a random-primed genomic BCL2 probe (pSP64/18-4RH, a 2.8-kb EcoRIHind111 fragment from the MBR; provided by Dr Tsujimoto, Osaka University Medical School, Osaka, Japan). For each cloned PCR product, at least three plaques were grown. Single-strand DNA was purified and sequenced using the Sequenase Version 2.0 DNA Sequencing Kit with M13-sequencing forward primers ( U S Biochemical, Cleveland, OH). Alternatively, individual positive PCR products purified from agarose (NuSieve GTG agarose; FMC. Rockland, ME) gels were sequenced directly with the cycle-sequencing kit purchased from Perkin-Elmer using the "P-dATP end-labeled JH consensus primer or, in some cases, also the BCU-MBR2 primer. For analysis, the Genetics Computer Group sequence analysis software package (GenBank DNA databank, release 66.0; GCG, Wisconsin) was applied. The program Fasta was used for nucleic acid homologies with word size equal to 6. For homology to D-regions, identity of eight or more nucleotides was required.
Sensitivity of PCR. Serial dilutions of t(14; 18)-carrying tumor cells diluted in noma1 cells (1 in IO up to 1 in 10' cells), were used to determine the sensitivity of PCR. The seminested touchdown PCR enabled us to detect amplified sequences from approximately one t(14; Il)-carrying lymphoma cell diluted in IO' normal cells as visualized in ethidium bromide-stained gels. In pilot experiments, more reliable results were obtained by seminested PCR than by using a completely nested PCR with inner JH and BCL2 primers.'' To increase the number of target cells, and thereby further increase the sensitivity, and to detect very rare BCL2IJH rearrangements, all DNA samples were independently tested in five to seven PCR experiments.
Control for contamination. All standard precautions were taken
For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From to avoid contamination of amplification products." In each experiment, negative (water and placenta DNA) and positive controls [t( 14; 18)-containing lymphoma cells] were simultaneously tested. To exclude that contamination was caused by spurious carryover of amplification products during the preparation of stage 2 PCR, this stage 2 PCR was repeated twice in all positively hybridizing cases using two independently prepared new dilutions of the stage 1 PCR products. Samples with consistently (three times) positive results after hybridization with the JH and RCL2 probes were considered to be truly positive and were used for DNA sequencing. Samples with inconsistent results (the first time positive and the second and third times negative) were considered to be contaminated and. therefore, were scored as negative.
Exclusion qf PCR rrrtifircts. The possibility that the products were generated by in vitro PCR artifacts, particularly by false annealing of primers, was evaluated by ( I ) hybridization of all PCR products with the internal RCL2-MBR3.S probe and the JH probe, (2) nucleotide sequence analysis. (3) reproducibility experiments to test whether possible PCR artifacts generated during stage 2 PCR could be reproduced by repeating stage 2 PCR only. and (4) reproducibility experiments to test whether possible PCR artifacts generated during stage 1 and/or stage 2 PCR could be reproduced by repeating the total PCR procedure on the original DNA sample (performed five to seven times).
As shown in For reproducibility analysis of stage 2 PCR. we twice repeated stage 2 as described above. This analysis showed that some products that did not hybridize with the BCL2-MBR3.S and JH probes (Fig   2) also could not be reproduced in these repeat experiments, indicating that they were caused by an artifact generated during stage 2 PCR .
For reproducibility analysis of the whole PCR experiment, we performed five to seven completely independent FCR experiments on the original DNA samples of all cell fractions of the nine donors. The products in 226 (not visible on gel, not hybridizing with the BCL-2 probe), 22M. 22T, and 23T (visible on gel but not hybridizing with either probes) were considered as PCR artifacts. In several lanes, multiple bands with a size of approximately 100 t o 300 bp hybridized with both probes. As explained in Materials and Methods and in Fig   1 , hybridization with the BCU-MBR3.5 probe gives the best information on both the specificity and copy number of the products. In 22B. three almost overlapping bands of 150 t o 200 bp were present, with t w o of these being sequenced (breakpoints n and q; a third weak band indicated by a small block was better seen in another run). Similarly, two products could be identified in 23M (c and r) and in 238 (d and el, and one product could be identified in 248 (g). Note the strong differences in intensity of the bands depending on the hybridization with the BCU-MBR3.5 or the JH probe. (Band e gave a very weak signal after hybridization with the JH probe, which was clearly visible after prolonged overnight exposure of the autoradiograph; this weak hybridization is due to the small template of 38 nucleotides for this probe in this case.) As explained in Materials and Methods and in Fig 1, the higher bands with a size of approximately 300 t o 1,200 bp are generated by the use of the JH5 primer during stage 1 and the consensus JH primer during stage 2 of PCR. Sequence analysis of t w o of these bands with both JH and B C U sequencing primers (d and e, respectively) confirmed this origin. Additionally, sequencing of the approximately 550-bp fragment in 248 showed the presence of the expected JH4 sequences (the breakpoint itself could not be sequenced from this band). In 228 and 23M, very low copy numbers were present in these higher bands IC), and sequencing was not possible. Note that the distances between the individual higher bands and between the higher and lower bands correlate with the genomic distances between the individual JH gene segments.
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All PCR products were again hybridized with both probes, and all positive products with a size range of approximately 100 to 300 bp were again sequenced as described above. Identification of identical breakpoint sequences in these independent tests on the same cell fractions within the same individual makes it highly unlikely that the products are the result of annealing artifacts and subsequent amplification of nonsense templates. Tables 1 and 2 show that 9 of the 17 unique sequences could be reproduced two to six times in independent PCR experiments.
Interpretation of PCR results. One experiment is shown in Fig  2. All PCR products ranging from approximately 100 to 300 bp hybridizing to both probes contained bona fide t(14; 18) breakpoints ( Table 2) . In this size range, multiple hybridizing bands could be detected in several lanes (for instance, fractions 22B, 23M, 23B). As evidenced by sequence analysis, these multiple bands represented multiple independent t(14; 18) breakpoints. In addition to these lower bands, larger products with a size range of 300 to 1,200 bp hybridized with both the BCL2-MBR3.5 and JH probes. Sequence analysis of two of these bands (Fig 2, d and e) and a similar band in the positive control follicular lymphoma with a breakpoint at JH4 showed the presence of identical BCL2IJH breakpoints and contiguous downstream JH gene segments. The generation of these larger products is explained by the use of a JH5 primer during stage 1 PCR and the use of a JH consensus primer in stage 2 PCR. In contrast to the JH5 primer, the JH consensus primer anneals to all JH gene segments and, therefore, will generate multiple fragments if a breakpoint occurs at JH 1-4, as shown for case 23 in Fig 1. As shown in Fig 2, many relatively small PCR products with a size range of 1 0 0 to 300 bp gave a relatively strong signal with the BCL2-MBR3.5 oligonucleotide probe but gave a relatively weak signal with the genomic JH probe. This is explained by a relatively small template for hybridization with the JH probe (eg, Fig 2, n and q in lane 22B, with a template of 46 and 48 bp, respectively). In reverse, the higher bands of 300 to 1,200 bp often gave weak hybridization signals with the BCL2-MBR3.5 oligonucleotide probe and strong hybridization signals with the genomic JH probe. This is explained by a relatively very low copy number of these PCR products in combination with the relatively long JH template for the JH probe, as shown in Fig 1. Notably, only the hybridization signal with the BCL2-MBR3.5 probe reflects the real copy number of amplification products.
RESULTS
To detect possible rare t( 14; 18)-carrying B cells in healthy individuals and to verify these breakpoints, we used the following strategy. (1) DNA was prepared from granulocytes, mononuclear cells, and from FACS-purified B cells and T cells of nine blood bank donors. (2) All DNA samples were independently tested by seminested PCR in five to seven separate experiments. (3) All PCR products were size-fractionated and hybridized with an internal BCL2 probe and a JH probe. (4) All double-positive hybridizing products were twice retested for stage 2 of seminested PCR. ( 5 ) All products that were consistently positive and that had a size range of approximately 100 to 300 bp were sequenced after cloning or were directly sequenced. (6) Some double-positive hybridizing products with a size range of approximately 300 to 1,200 bp were also sequenced to prove their origin from BCL2IJH and contiguous downstream JH gene segments.
The analysis showed the presence of t(14; 18) breakpoints in six of nine blood donors (Table 1) Sequence analysis of PCR products showed the presence of bona fide t( 14; 18) breakpoints, localized within the known subclusters of the MBR of BCL2 and at the 5' side of JH or DH segments of the Ig heavy chain locus ( Table 2 ). DHregions were detected in at least six sequences, and N-regions were identified in all sequences, indicative of an origin from terminal transferase (TdT)-positive bone marrow precursor B cells. In two cases, we were also able to sequence higher bands with a size of greater than 300 bp. This showed the presence of contiguous JH gene segments downstream of the BCL2IJH breakpoint. This configuration is similar to the breakpoints in follicular lymphoma.3'5~"
The presence of multiple bands with a size of approximately 100 to 300 bp in single individuals indicated the presence of more than one t( 14; 18) breakpoint in these donors (eg, Fig 2, donors 22 and 23 ). Sequence analysis of the individual bands within this size range confirmed this observation: in total, we identified one unique breakpoint in donors 24 and 25, two different breakpoints in donor 32, three breakpoints in donor 27, four breakpoints in donor 23, and five independent breakpoints in donor 22 (Tables 1 and  2 ).
The sensitivity of a single PCR experiment ultimately depends on the maximal number of cells that are tested per reaction tube (usually 1 X lo5 to 2 X lo5 cells; ie, 1 pg of DNA). To detect extremely rare cells with a t( 14; 18) breakpoint at a level of 1 in 10' cells or less as found in previous experiments on hyperplastic tonsils," we performed five to seven repeat experiments on the original DNA samples. These repeat experiments showed variable levels of reproducibility: for instance, breakpoint p was identified only once, but breakpoint k was detected six times in a single donor. The stochastic distribution indicates that many breakpoints occurred at a frequency of less than 1 in 10' B cells.
Contamination by spurious PCR products was ruled out by analysis of simultaneously performed negative controls, by triplicating stage 2 of semi-nested PCR, and by DNA sequence analysis of the breakpoint regions that proved to be unique for single individuals. Moreover, the nonrandom distribution in B cells, T cells, and granulocytes supports the notion that the products could not be generated by unwanted carryover. Nevertheless, crosscontamination of PCR products between samples was detected in two instances: in case 24, sequence k, we were able to retrospectively assign this sequence to donor 32 (Table 1) . Possibly, contamination of the same products was also the cause of the incidental positive results in the T cells and granulocytes of donor 32 in experiments 6 and 7. Furthermore, we could not identify the origin of sequence r that was found once in donor 23 and once in donor 32 (Tables 1 and 2 ). Sequence r was identified once in donor 23 and once in donor 32. As r was not observed in other independent PCR experiments, we could not ascertain the origin of this sequence and did not include this sequence in our analysis.
t No amplification products visible on gel and ambiguous hybridization results for the BCL2-MBR3. 5 and JH probes after fivefold repetition of stage 2 PCR; consequently, insufficient PCR product for cloning and direct sequencing.
t In fraction 246, experiment 6, two bands hybridizing with both the BCU-MBR3. 5 and JH probes were detected; sequence analysis showed products g and k. A s k was identified only once in this donor, and as it was independently and repeatedly identified in other experiments on donor 32, the presence of k in donor 24 was considered as contamination.
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It is also very unlikely that our products are the result of incidental in vitro PCR artifacts caused by erroneous annealing of primers, as the sequences represent bona fide breakpoints similar to those observed in follicular lymphoma, and as identical sequences were detected in completely independent repeat PCR experiments on the original DNA samples. Notably, some artifacts were produced (eg ,  Fig 2) , but these products did not hybridize with both probes and could not be reproduced in repeat experiments.
DISCUSSION
Chromosomal translocations involving an oncogene and one of the Ig genes are characteristically found in human Bcell lymphomas. Deregulation of the involved oncogene is supposed to be an essential mechanism in the genesis of these tumors. However, similar to solid cancer, malignant lymphomas are likely caused by the occurrence of a series of various oncogenic events. Theoretically, this multistep mechanism might permit us to find B cells that have accumulated only one or a few but not all hits necessary to establish the malignant phenotype. In the present study, we show that such cells with translocation t(14; 18) can be identified in most normal individuals. Occasional chromosomal translocations and inversions involving T-cell receptor (TCR) genes, including t(7;14)(p13;qll) and inv[l4], have been described in T cells of normal individual^.'^,^^ They are ascribed to the occurrence of illegitimate V, D, and J recombinations between different TCR loci in early thymocytes and, hence, bear molecular similarity with the currently described t(14; 18) breakpoints in B cells of healthy individuals. However, the consequence of the latter is essentially different because of the involvement of an oncogene in the t( 14; 18) translocation.
The translocation t( 14; 18) is observed in about 80% to 90% of all follicular lymphomas. In addition, it is also detected in a minor subset of large B-cell lymphomas and rare cases of acute lymphocytic leukemia that may represent secondary transformed follicular lymphomas.' The distinct clustering of breakpoints in the MBR and minor cluster region (rncr) of BCL2, in combination with its partners at 14q32, make t(14; 18) an ideal target for amplification by PCR. Since the introduction of this assay," multiple studies How can we explain the conflicting results on blood cells in normal individuals in the present and previous studies?'"'' In previous studies, either whole leukocyte preparations or mononuclear cell fractions were tested. Usually, 1 X I d to 2 X IO5 mononuclear blood cells are tested by one single PCR assay of 1 pg of genomic DNA. Such samples contain only 10 X lo3 to 20 X 10' (5% to 15%) B cells. BM mononuclear cell samples will contain even fewer target cells: ie, 1 X IO' to 5 X lo3 (2% to 5%) B cells, including precursor B cells. Thus, the negative results obtained by others can be explained by a relatively low number of target B cells in unpurified cell fractions, even in the case of repeat experiments.I6 This is supported by our own results on mononuclear blood cell fractions that were positive in only 4 of 47 independent experiments (Table l). As this frequency is not significantly different from that in T cells and granulocytes, such rare events in mononuclear cells might easily be misinterpreted as carryover of PCR products.
The prevalence of t( 14; 18)-carrying cells in normal individuals can be roughly estimated from our experiments. The stochastic nature of the results in consecutive experiments on purified B-cell fractions and the very low frequency in mononuclear cells containing 4.7% to 13.0% B cells, in conjunction with the results of simultaneously performed dilution experiments on positive control cells, indicate a frequency of about one t(14; 18)-carrying cell per IO' or fewer B cells. This implies that normal individuals may accommodate 1 X 10' to 20 X IO3 circulating B cells with a t(14; 18) translocation and an unknown number of similar cells in lymphoid tissues. The total frequency oft( 14; 18) breakpoir,tcarrying cells will be higher, as we did not analyze breakpoints at JH6 and/or within the rncr of BCL2, which comprise a considerable part of the translocations in follicular lymph~ma.~' Furthermore, the interindividual differences in the number and size of the t(14; 18)-carrying clones, a phenomenon also found in lymphoid tissues with follicular hyperpla~ia,",~~ suggest that normal individuals may have different rates of aberrant recombinations within precursor B cells or may exhibit differences in release, survival, and expansion of t( 14; 18)-positive B cells. As the blood donors were tested anonymously, we could not investigate the fate of the t(14; 18)-carrying cells by follow-up analysis. The high frequency of the t(14; 18) breakpoints in more than half of normal individuals and the low incidence of follicular lymphoma (3/100,000 inhabitants per year in The Netherlands) exclude the possibility that all t(14; 18)-carrying cells represent subclinical follicular lymphoma. Most importantly, it also indicates that not the t( 14; 18) translocation but other, additional events are rate-limiting in the genesis of follicular lymphoma. However, we cannot exclude that individuals with a high number of circulating t( 14; 18)-carrying B cells have a relatively high risk of developing follicular lymphoma, In that context, it would be of interest to study the frequency and persistence of t(14; IWcarrying cells in For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From elderly people known to be at a higher risk of developing follicular lymphoma. In an attempt to evaluate the in vitro persistence of t(14; 18)-carrying cells and eventually to clone these cells, we were able to maintain two unique t( 14; 18) clones in cell culture for at least 5 weeks after Epstein-Barr virus transformation (data not shown).
On the basis of our findings, we speculate that the translocation t( 14; 18) is regularly generated in bone marrow precursor B cells of healthy individuals and that t( 14; 18)-carrying daughter cells enter the blood stream and home to lymphoid tissues. Deregulation of BCL2 in these cells may enhance cell survival, thereby providing a pool of longliving and circulating t( 14; 18)-carrying B cells detected in our PCR experiments. These cells may selectively accumulate additional genetic damage, especially as high expression of BCL2 can prevent apoptosis normally induced by various toxic Accumulation of genetic damage in one of the multiple t( 14; 18)-carrying clones, probably in combination with antigen-driven proliferation within the germinal cent e r~,~* may ultimately lead to the malignant phenotype of follicular lymphoma. The idea that chromosomal translocations may precede other oncogenic steps and that many cells with chromosomal translocations do not become tumorigenic is supported by experimental work in animals. BCL2IIgH transgenic mice will develop lymphoma only after acquisition of secondary oncogenic events, such as a rearrangement of MYC. Interestingly, MYC rearrangements alone are also incapable of causing a lymphoma, as has been recently demonstrated in pristane-induced plasmacytomas in BALB-C mice.39 Similar to the t(8;14) and variant translocations in human Burkitt's lymphoma, these plasmacytomas contain a translocation involving MYC and an Ig locus. Using PCR, multiple MYC/IgH rearrangements could be detected early after pristane injection and several months before the development of the monoclonal plasmacytoma.
The present observations may have important clinical consequences. Previous studies on the clinical significance of minimal residual disease as defined by amplifiable t( 14; 18) products have shown that myeloablative therapy followed by autologous reinfusion of extensively purged bone marrow cells might be of benefit for patients with t( 14; 18)-positive l y m p h~m a .~,~' Gribben et a140. 41 showed that the absence of amplifiable sequences in the purged BM, as well as in BM and blood samples obtained after transplantation, was correlated with a long disease-free survival. As shown in the present study, use of unpurified samples results in a limited number of target cells for amplification and, hence, a certain threshold for the sensitivity of the PCR. Therefore, the PCR results of Gribben et a1 may have reflected the amount of tumor burden present after therapy, rather than indicating whether or not tumor cells were completely eradicated. An increase in the number of target cells by (repeat) PCR analysis of purified B cells, as presently performed, will enhance the sensitivity of the assay but might also result in detection of many irrelevant, tumor-unrelated, t( 14; 18)-positive cells and, hence, would necessitate laborious sequence analysis of all PCR products and comparison with the original tumor material. On the other hand, Price et a14* described the persistence of t(14; 18)-canying cells at 10 to 20 years after obtaining a continuous and complete remission from follicular lymphoma. These residual cells contained a t(14; 18) breakpoint similar to that in the original tumor, proving the clonal relationship. These cells could represent relatively harmless precursor tumor cells that lack the full set of oncogenic events necessary for regrowth into follicular lymphoma.
NOTE ADDED IN PROOF
In a recent report (Proc Natl Acad USA 91:8910, 1994), Liu et a1 identified t( 14; 18)-carrying clones in peripheral blood cells of normal blood bank donors. Translocations were copurified with B cells isolated with CD19-coated magnetic beads. These data are in line with the present observations and our previous report on t( 14; 18) in hyperplastic tonsils. In addition, these investigators observed a significant increase of t(14; 18)-carrying cells with age.
